Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo

Circulation Research

Volumn 96, Issue 4, 2005, Pages 435-441

  Asleh, Rabea ^a   Guetta, Julia ^a   Kalet Litman, Shiri ^a   Miller Lotan, Rachel ^a   Levy, Andrew P ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Diabetes; Haptoglobin; Hemoglobin; Iron; Oxidative stress

Indexed keywords

DEFEROXAMINE; HAPTOGLOBIN; HEMOGLOBIN; IRON;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; GENOTYPE; IRON CHELATION; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL;

ALLELES; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DEFEROXAMINE; DIABETES MELLITUS, EXPERIMENTAL; FLUORESCEINS; GENOTYPE; GLUCOSE; HAPTOGLOBINS; HEMOGLOBIN A, GLYCOSYLATED; HEMOGLOBINS; HUMANS; IRON; IRON CHELATING AGENTS; KIDNEY; LIPID PEROXIDATION; MICE; MODELS, BIOLOGICAL; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN ISOFORMS; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSGENES;

EID: 14844345323     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000156653.05853.b9     Document Type: Article

References (45)

1. Bowman BH, Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet. 1982;12:189-261.
2. Levy AP, Roguin A, Hochberg I, Herer P, Marsh S, Nakhoul FM, Skorecki K. Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med. 2000;343:969-970.
3. Levy AP, Hochberg I, Jablonski K, Resnick HE., Lee ET, Best L, Howard BV. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol. 2002;40:1984-1990.
4. Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the one year period after PTCA in individuals with diabetes. Diabetes Care. 2003;26:2628-2631.
5. Suleiman M, Kapeliovich MR, Roguin A, Aaronson D, Meisel SR, Shochat M, Reisner SA, Hammerman H, Levy NS, Levy AP. Haptoglobin phenotype and mortality in the 30 day period following acute myocardial infarction. Diabetes Care. 2003;26:2699-2700.
6. Levy AP, Larson MG, Corey D, Lotan R, Vita JA, Benjamin EJ. Haptoglobin phenotype and prevalent coronary heart disease in the Framingham Cohort. Atherosclerosis. 2004;172:361-365.
7. Miller YI, Altamentova SM, Shaklai N. Oxidation of low-density lipoprotein by hemoglobin stems from a heme-initiated globin radical: antioxidant role of haptoglobin. Biochemistry. 1997;36:12189-12198.
8. Bunn HF, Jandl JH. Exchange of heme among hemoglobins and between hemoglobin and albumin. J Biol Chem. 1968;243:465-475.
9. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198-201.
10. Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, Levy AP. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003;92:1193-1200.
11. Sullivan JL. Iron and sex differences in heart disease risk. Lancet. 1981;1:1293-1294.
12. Danesh J, Appleby P. Coronary heart disease and iron status: meta analysis of prospective studies. Circulation. 1999;99:852-854.
13. Baer DM, Tekawa IS, Hurley LB. Iron stores are not associated with acute myocardial infarction. Circulation. 1994;89:2915-2918.
14. Armaganijan D, Batlouni M. Serum ferritin levels and other indicators of organic iron as risk factors or markers in coronary artery disease. Rev Port Card. 2003;22:185-195.
15. Crichton RR, Charloteaux-Wauters M. Iron transport and storage. Eur J Biochem. 1987;164:485-506.
16. Goswami T, Rolfs A, Hediger MA. Iron transport: emerging roles in health and disease. Biochem Cell Biol. 2002;80:679-689.
17. Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kid Dis. 2003;41:80-83.
18. Mulligan M, Althaus B, Linder MC. Non-ferritin, non-heme iron pools in rat tissues. Int J Biochem. 1986;18:791-798.
19. Jacobs A. Low molecular weight intracellular iron transport compounds. Blood. 1977;50:433-439.
20. Halliwell B, Gutterridge JMC. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys. 1986;246:501-514.
21. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF, Vita JA. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2002;103:2799-2804.
22. Delanghe JR, Langlois MR. Haptoglobin polymorphism and body iron stores. Clin Chem Lab Med. 2002;40:212-216.
23. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102:2670-2677.
24. Qian M, Liu M, Eaton JW. Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Comm. 1998;250:385-389.
25. Panter SS. Release of iron from hemoglobin. Methods Enzymology. 1994;231:502-514.
26. Ferrali M, Signorini C, Caciotti B, Sugherinin L, CiccoliL, Giachetti D, Comporti M. Protection against oxidative damage of erythrocyte membrane by the flavonoid quercetin and its relation to iron chelating activity. FEBS Lett. 1997;416:123-129.
27. Gutteridge JMC. Iron promoters of the Fenton reaction and lipid peroxidation can be released from hemoglobin by peroxides. FEBS Lett. 1986;201:291-295.
28. Puppo A, Halliwell B. Formation of hydroxyl radicals from hydrogen peroxides in the presence of iron: is hemoglobin a biological Fenton reagent? Biochem J. 1988;249:185-190.
29. Dickerson RE, Geis J. Hemoglobin-Structure, Function, Evolution and Pathology. Menlo Park, NJ: Benjamin Cummins; 1983.
30. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, Oh Y, Rosenfeld RG. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor binding protein related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology, 2000;142:1760-1769.
31. Rich RL, Myszka DG. Advances in surface plasmon resonance biosensor analysis. Curr Opin Biotech. 2000;11:54-61.
32. Aviram M, Vaya J. Markers for low-density lipoprotein oxidation. Meth Enzym. 2001;335:244-256.
33. 2 in cultured endothelial cells. Arch Biochem Biophys. 1993;302:348-355.
34. el-Saadani M, Esterbauer H, el-Sayed M, Goher M, Nassar AY, Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res. 1989;30:627-630.
35. Yang F, Linehan LA, Friedrichs WE, Lalley PA, Sakaguchi AY, Bowman BH. Characterization of the mouse haptoglobin gene. Genomics. 1993;18:374-380.
36. Lim SK, Kim H, Lim SK, bin Ali A, Lim YK, Wang Y, Chong SM, Costantini F, Baumman H. Increased susceptibility in Hp knockout mice during acute hemolysis. Blood. 1998;92:1870-1877.
37. Yang F, Ghio AJ, Herbert DC, Weaker FJ, Walter CA, Coalson JJ. Pulmonary expression of the human haptoglobin gene. Am J Respir Cell Mol Biol. 2000;23:277-282.
38. Bartfay WJ, Butany J, Lehotay DC, Sole MJ, Hou D, Bartfay E, Liu PP. A biochemical, histochemical and electron microscopic study on the effects of iron loading on the hearts of mice. Card Path. 1999;8:305-314.
39. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42:1589-1600.
40. Kruszewski M. The role of the labile iron pool in cardiovascular diseases. Acta Biochim Pol. 2004;51:471-480.
41. Bamm VV, Tsemakhovich VA, Shaklai M, Shaklai N. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry. 2004;43:3899-3906.
42. d'Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Long term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res. 2003;92:88-95.
43. Langlois MR, Delanghe JR, DeBuyzere ML, Bernard DR, Ouyang J, Effect of haptoglobin on the metabolism of vitamin C. Am J Clin Nut. 1997;66:606-610.
44. Delanghe JR, Langlois M, Duprez D, DeBuyzere ML, Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis. 1999;145:287-292.
45. Levy AP, Friedenberg P, Lotan R, Ouyang P, Triputti M, Higginson L, Cobb FR, Tardif JC, Bittner V, Howard BV. The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women. Diabetes Care. 2004;27:925-930.